Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a report released on Tuesday. They currently have $49.00 price target on the stock.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other research analysts also recently issued reports about the company. ValuEngine raised Catalent from a hold rating to a buy rating in a research note on Wednesday, February 7th. Bank of America boosted their price objective on Catalent from $47.00 to $49.00 and gave the company a buy rating in a research note on Tuesday, February 6th. Royal Bank of Canada set a $48.00 price objective on Catalent and gave the company a buy rating in a research note on Monday, February 5th. Goldman Sachs Group initiated coverage on Catalent in a research note on Wednesday, January 24th. They issued a buy rating and a $50.00 price objective on the stock. Finally, First Analysis initiated coverage on Catalent in a research note on Friday, January 5th. They issued an equal weight rating on the stock. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Catalent presently has an average rating of Buy and a consensus price target of $45.70.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The company had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The firm’s revenue was up 25.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.27 EPS. sell-side analysts predict that Catalent will post 1.53 earnings per share for the current fiscal year.
In related news, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.70% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Stifel Financial Corp increased its holdings in Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after purchasing an additional 96 shares in the last quarter. Royal Bank of Canada increased its holdings in Catalent by 46.7% during the 2nd quarter. Royal Bank of Canada now owns 35,029 shares of the company’s stock worth $1,230,000 after purchasing an additional 11,151 shares in the last quarter. California State Teachers Retirement System increased its holdings in Catalent by 13.6% during the 2nd quarter. California State Teachers Retirement System now owns 222,934 shares of the company’s stock worth $7,825,000 after purchasing an additional 26,707 shares in the last quarter. Nomura Holdings Inc. bought a new stake in Catalent during the 2nd quarter worth approximately $220,000. Finally, Oakbrook Investments LLC bought a new stake in Catalent during the 3rd quarter worth approximately $343,000. 99.82% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2018/02/21/catalent-ctlt-upgraded-at-zacks-investment-research.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.